Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/798822

Contents of this Issue

Navigation

Page 17 of 47

16 Clinical OMICs March/April 2017 www.clinicalomics.com Diagnostics Less Is More UPMC Clinical Trial to Examine If More Precise Molecular Profiling of Thyroid Cancer Patients Can Decrease Thyroidectomies By Meghaan Ferreira, Contributing Editor W hen it comes to thyroid cancer, is less more? Research- ers at the University of Pittsburgh Medical Center (UPMC) aim to answer this question with the first-ever pro- spective clinical trial to test whether molecular profiling can enable tailored, thyroid-preserving surgeries instead of total thyroidectomies by preoperatively identifying nonaggres- sive, low-risk thyroid cancer cases . In addition to reducing the risk for surgical complications, removing only half of the thyroid, also referred to as a lobectomy, may leave enough of the butterfly-shaped gland intact to avoid the need for daily hormone replacement therapy . The study will implement ThyroSeq v . 2, one of several molecular profiling tools on the market designed to iden- tify the genomic signatures of thyroid cancer . Initially developed by a scientific team lead by Yuri Nikiforov, M.D., Ph . D . at UPMC, ThyroSeq is currently used to predict the risk of thyroid cancer in a subset of patients, which accounts for approximately 20% of all biopsies, where conventional cytology cannot differentiate between malignant and benign thyroid nodules . The latest version of ThyroSeq uses next-generation sequencing to test fine needle biopsies for the presence of 42 different thyroid cancer-associated mark- ers across 14 genes . "As we become more experienced with these genetic markers, we're getting more information about the biologic behavior and disease characteristics of tumors, and we're seeing genotype-phenotype associations—certain genetic signatures that seem to be associated with certain cancer phenotypes," remarked the principal investigator of the trial Lin- wah Yip, M . D . Dr . Yip and her colleagues saw these emerging geno- type-phenotype associations as a potential answer to a mul- titude of questions prompted by new guidelines released by the American Thyroid Association (ATA) in 2015 . In contrast to earlier editions, which recommended complete thyroid removal for virtually all cancers, the latest edition advocates less aggressive treatments for low-risk cancers, including removal of only half the thyroid, and less frequent use of radioactive iodine treatment . One reason the new guidelines emphasize less aggres- sive treatment for low-risk cancers is that the discovery of small cancers found incidentally during imaging studies "If we could cut the healthcare dollars spent on unnecessary thyroidectomies, [we would achieve] a wonderful goal." —Sally Carty, M.D., UPMC

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017